Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 13;18(1):1247.
doi: 10.1186/s12885-018-5156-1.

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution

Anastasios Kyriazoglou  1 , Michael Liontos  2 , Dimitrios C Ziogas  2 , Flora Zagouri  2 , Kostantinos Koutsoukos  2 , Giorgos Tsironis  2 , Anna Tsiara  2 , Maria Kaparelou  2 , Roubini Zakopoulou  2 , Nikolaos Thomakos  3 , Dimitrios Haidopoulos  3 , Irene Papaspyrou  4 , Alexandros Rodolakis  3 , Aristotelis Bamias  2 , Meletios Athanasios Dimopoulos  2
Affiliations

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution

Anastasios Kyriazoglou et al. BMC Cancer. .

Abstract

Background: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages.

Methods: We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression.

Results: Data were retrieved from 61 women with a median age of 53 (range: 27-78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028).

Conclusions: Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas.

Keywords: Mitotic index; Prognostic factors; Uterine sarcomas.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The ethics committee of General Hospital Alexandra approved the study and patients have signed informed consent for the analysis and publication of their data.

Consent for publication

Not applicable.

Competing interests

None of the authors have any competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
a Overall survival in months, b Time to event analysis, Overall survival in months in correlation with mitotic index, high mitotic index: > 15 mitoses/10HPF, low mitotic index: < 15 mitoses/10HPF
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bocker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 2002;86:116–119. - PubMed
    1. Fletcher CD. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11. - PubMed
    1. Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol. 2001;81(2):160–165. - PubMed
    1. Feng W, Malpica A, Robboy SJ, Gudlaugsson E, Hua K, Zhou X, Baak JP. Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. Int J Gynecol Pathol. 2013;32(3):299–306. - PubMed
    1. Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013;20(7):2364–2372. - PMC - PubMed

MeSH terms

LinkOut - more resources